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Multiple Tumor Suppressor Pathways
Negatively Regulate Telomerase
telomeres, telomerase has been shown to protect the
single-stranded ends of chromosomes and may have a
role in maintaining telomeres in a structure that is not
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recognized as DNA damage, thereby preventing activa-2 Howard Hughes Medical Institute
tion of the cellular senescence program (Stewart et al.,3 Department of Molecular and Human Genetics
2003).Baylor College of Medicine
Telomerase has been implicated in the maintenanceOne Baylor Plaza
of stem cell function. A variety of self-renewing tissuesHouston, Texas 77030
have been shown to express telomerase activity includ-
ing keratinocytes, the basal layer of the epidermis, and
hematopoetic cells (Forsyth et al., 2002; Mason, 2003).Summary
In addition, Dyskeratosis congenita, a rare skin and bone
marrow failure syndrome, is caused by defective telo-Telomerase expression is repressed in most somatic
mere maintenance in stem cells. An autosomal dominantcells but is observed in stem cells and a high percent-
form is due to mutations in the RNA component of telo-age of human cancers and has been hypothesized to
merase, hTR (Vulliamy et al., 2001). Patients with thiscontribute to tumorigenesis and maintenance of stem
form of the disease are more severely affected in latercell states. To explore telomerase regulation, we em-
generations, possibly due to the inheritance of short-ployed a general genetic screen to identify negative
ened telomeres. The defects in stem cell function asso-regulators of hTERT. We discovered three tumor sup-
ciated with this disease and the general absence ofpressor/oncogene pathways involved in hTERT re-
telomerase activity in somatic cells has lent credencepression. One, the Mad1/c-Myc pathway, had been
to the hypothesis that differentiating cells turn off telo-previously implicated in hTERT regulation. The sec-
merase, which may contribute to limiting their replicativeond, SIP1, a transcriptional target of the TGF- path-
potential. In addition, mice lacking telomerase eventu-way, mediates the TGF- regulated repression of
ally show impairment of organs composed of highlyhTERT. The third, the tumor suppressor Menin, is a
proliferative tissues and premature aging (Blasco et al.,direct repressor of hTERT. Depleting Menin immortal-
1997; Lee et al., 1998; Rudolph et al., 1999; Artandi andizes primary human fibroblasts and causes a transfor-
DePinho, 2000).mation phenotype when coupled with expression of
The ability of cells to replicate indefinitely has beenSV40 Large and Small T antigen and oncogenic ras.
linked to telomerase expression. A high percentage ofThese studies suggest that multiple tumor suppres-
tumor cells that take on immortalized characteristicssor/oncogene pathways coordinately repress hTERT
show telomerase activity (Kim et al., 1994; Greider andexpression and imply that telomerase is reactivated
Blackburn, 1996; Shay and Bacchetti, 1997; Cong et al.,in human tumors through oncogenic mutations.
2002), and it has been suggested that hTERT expression
may be one of the six key events common to cancerIntroduction
(Hanahan and Weinberg, 2000). In addition, ectopic ex-
pression of hTERT in primary fibroblasts prevents repli-The replication of linear chromosomes by DNA polymer-
cative senescence in vitro (Morales et al., 1999; Jiang etases fails to completely duplicate the ends of chromo-
al., 1999; Zhu et al., 1999; Hahn et al., 1999). Surprisingly,somes. To complete the replication of chromosomal
wild-type human fibroblasts in culture escape senes-
ends, cells have evolved a specialized reverse tran-
cence extremely rarely (Wright et al., 1989; Counter et al.,
scriptase called telomerase (Greider and Blackburn,
1992; Stewart and Weinberg, 2002). Since telomerase
1987), which adds a repeated sequence onto the ends expression is sufficient for this escape, it must occur
of newly replicated chromosomes. Telomerase consists only very rarely. This suggests that hTERT expression
of a protein component, hTERT, and an RNA component is under stringent negative control (Cong et al., 2002;
(hTR) containing the template for synthesis of the repeat Ducrest et al., 2002).
unit added onto the ends of chromosomes (Greider, Considerable support exists for the hypothesis that
1996; McEachern et al., 2000; Stewart and Weinberg. telomerase expression contributes to human cancer. In
2000). Telomerase activity (Greider, 1998; Aisner et al., addition to its role in immortalizing fibroblasts, hTERT
2002; Cong et al., 2002) and hTERT expression (Naka- can cooperate with activated ras and Large and Small
mura et al. 1997; Meyerson et al., 1997; Hahn and Meyer- T antigen to transform primary human cells (Hahn et al.,
son, 2001; Ducrest et al., 2002) are absent in most so- 1999). However, although hTERT is expressed in 90%
matic cells and, as a result, chromosome ends continue of human cancers, it has not been established that its
to shorten as somatic cells proliferate. This shortening expression is more than correlative. Unlike most onco-
of chromosomal ends is thought to decrease the replica- genes, no amplification or rearrangements of the hTERT
tive potential of cells and eventually leads cells into gene to date have been identified in tumors to support
senescence or into crisis, which results in cell death (de the idea that this gene was specifically turned on in
Lange, 1994). In addition to preventing shortening of tumor cells. In the absence of alterations of the hTERT
genomic locus to activate it in tumor cells, it would be
expected that if telomerase expression is specifically*Correspondence: selledge@bcm.tmc.edu
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were identified using enhanced retroviral mutagens (Liu
et al., 2000) (ERM). ERM is a retroviral vector that con-
tains an epitope tag and a splice donor under the control
of a tetracycline-responsive element. Random viral inte-
gration will occasionally result in insertion into a tran-
scriptional unit to produce a gene fusion in which the
endogenous gene is fused in frame to the epitope tag
and placed under Tet control. We coinfected these cells
with a retrovirus encoding Tet-off to place the ERM
promoter under Tet control. The elevated expression of
negative regulators of hTERT in a subset of ERM in-
fected cells should result in reduced GFP expression in
these cells. This population of cells displaying a reduc-
tion in GFP levels were identified and recovered by FACS
(Figure 2A, middle, asterisk region). The pooled candi-
dates identified in the first screen were then further ex-
amined by adding doxycycline to turn off expression of
genes under control of the ERM virus to ensure that the
reduction of GFP intensity was due to overexpression
of the insertion genes (Figure 2A, bottom, asterisk re-
gion). The cells sorted in the second screen for increased
GFP expression were collected by a single cell sorter
(autoclone). These cells were then examined again for
Tet-responsive GFP expression, and candidates show-
Figure 1. Schematic Outline of the Experimental Setup for Identifi- ing a greater than 3-fold change in GFP expression were
cation of Transcriptional Repressors of hTERT chosen for further study. Nine candidates were isolated,
For the primary screen, we infected reporter cells with enhanced and the identity of six insertion sites was determined
retroviral mutagens (ERM). Cells with reduced GFP intensity were by 3 RACE. As shown in Figure 2B, five of the candi-
sorted and expanded. As a secondary screen, doxycycline was dates are either transcriptional regulators, such as
added to repress the expression directed by the ERM retroviral
Menin (Agarwal et al., 1999; Heppner et al., 2001), Sip1insertions in these cells. Cells that restore GFP expression in the
(Comijn et al., 2001), Mad1 (Ayer et al., 1996), and hSir2presence of doxycycline were sorted by the single cell sorter (au-
(Vaziri et al., 2001) or are involved in signaling, such astoclone).
Rak, which encodes a protein kinase and has been
shown to interact with the retinoblastoma protein pRB
(Craven et al., 1995). Mad1 has been implicated in hTERTreactivated in tumor cells, mutations in the pathways
repression by several groups (Wang et al. 1998; Oh etthat regulate telomerase should be found in tumors.
al., 2000; Xu et al., 2001), thus validating our screeningIn addition to specific roles in cellular functions, telo-
strategy. In addition to the known genes, we identifiedmerase may have broader roles at the organismal level.
another protein in our screen that contained two BRCTTelomeres and telomerase have long been suspected
domains in the C terminus. We named this gene BRIT1to be agents of human aging (Cong et al., 2002; Blasco,
(BRCT-repeat inhibitor of hTERT expression).2002). Recently, a retrospective study examining the
To determine whether the genes we identified arecorrelation between telomere lengths and mortality in
genuine hTERT repressors, we transfected vectors ex-age-matched individuals discovered that individuals
pressing the individual proteins into HeLa cells andwith shorter telomeres have a significantly higher mortal-
quantified the changes in endogenous hTERT transcriptity rate (Cawthon et al., 2003). While further studies are
levels by RT-PCR. In control experiments, we could de-needed to support the validity of such claims, they raise
tect high levels of hTERT transcripts in HeLa (Oh et al.,the intriguing possibility that controlling telomere length
2000), MCF-7, and BJ-hTERT (Jiang et al., 1999) stablemay have the potential to affect mortality. To further
cells, which have been previously reported to highlyinvestigate the roles of telomerase in human biology
express hTERT (Figure 3A). In contrast, BJ cells (Jiangand establish the regulatory circuitry for transcription of
et al., 1999), a primary fibroblast cell line, as well ashTERT, we undertook a genetic screen to identify hTERT
U2OS and Saos-2 (Bryan et al., 1997), two ALT osteosar-regulators described herein.
coma cell lines, expressed no detectable hTERT mes-
sage. In the transfection experiments, we found that
Results all genes tested except hSIR2 significantly repressed
endogenous hTERT expression (Figure 3B; BRIT1 was
To examine the reactivation hypothesis and to identify not tested). These repressive effects were also sup-
potential tumor suppressors involved in hTERT repres- ported by reductions in hTERT protein levels as overex-
sion in normal cells, we established a genetic screen to pression of Menin or Mad1 significantly decreased hTERT
identify transcriptional repressors for hTERT in human protein levels in HeLa nuclear extracts (Figure 3C).
cells (Figure 1). HeLa cells, which normally express high Unexpectedly, human Sir2, a type-three histone de-
levels of hTERT transcripts, were stably transfected with acetylase, not only failed to repress, but also appeared
a GFP reporter driven by 2 kb of the hTERT promoter to increase hTERT expression when overexpressed.
Since our insertion library was N terminally tagged with(hTERT-2K). Negative regulators of hTERT expression
Genetic Repressors of Telomerase Expression
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Figure 2. The Identification of Candidate hTERT Repressors
(A) Sequential sorting of hTERT-GFP reporter cells (top) after ERM delivery (middle) and doxycycline addition (bottom). The cells were sorted
by FACS in the region marked with an asterisk during first, as well as second, screen.
(B) The number or cell clones collected from the screens and the identity of the repressor candidates as well as their inhibitory effects on
the GFP-reporter. The accession number for BRIT1 is NM_024596.
ERM, the possibility existed that the fusion protein was
inactive, resulting in a dominant-negative effect. In fact,
when we infected cells with a retrovirus expressing a
dominant-negative hSIR2 mutant (Vaziri et al., 2001), we
observed a slight reduction of hTERT mRNA levels. This
observation suggests that hSir2 may function as an
hTERT activator instead of a repressor.
While four of the five genes tested can reduce hTERT
expression when overproduced, it is not clear whether
they act as repressors when expressed at endogenous
levels in cells that do not express hTERT. Since the
regulation of hTERT behaves as a recessive trait (Oshi-
mura and Barrett, 1997; Kyo and Inoue, 2002), we antici-
pated that loss of hTERT repressors should reactivate
hTERT expression in hTERT negative cells. To address
this, we sought to reduce the expression levels of these
proteins using siRNA (Elbashir et al., 2001) in U2OS cells
that do not normally express hTERT. siRNAs against
individual candidate genes were transfected into U2OS
(A) Specific detection of hTERT RT-PCR products in the indicated
cell lines.
(B) RNA was prepared from HeLa cells transfected with expression
vectors for the indicated repressor candidates and analyzed for
endogenous hTERT expression levels by RT-PCR.
(C) Protein was prepared from HeLa cells transfected with expres-
sion vectors for the Menin and Mad1 and analyzed for endogenous
hTERT expression levels by Western blotting. The same amount of
nuclear extract from U2OS cells was included as a negative controlFigure 3. Testing the Effects of the Candidate hTERT Repressor on
Endogenous hTERT Expression for hTERT protein detection.
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884
Figure 4. Candidate Repressors Are Required In Vivo to Limit hTERT Expression
Cells treated with the indicated siRNAs were prepped for RNA or protein analysis as indicated. (A) Depletion of the repressor candidates by
siRNAs reactivated hTERT expression detected by RT-PCR (top) or Western blotting (bottom) in U2OS cells. (B) Depletion of SIP1 partially
rescued the inhibitory effect of TGF- on hTERT expression in MCF-7 cells. (C) hTERT expression in U2OS cells with or without p53 depletion
or in two HCT116 isogenic cell lines (top). hTERT expression levels were detected by RT-PCR using different numbers of PCR cycles in the
bottom panel. For the top, hTERT was detected using 31 cycles of PCR. In the bottom panel, hTERT was detected using 31, 29, or 28 cycles
as noted. In both cases, 16 cycles of PCR were used to detect GAPDH.
cells. As shown in Figure 4A (top), depletion of Rak, al., 1999). No difference in hTERT expression was de-
tected in these isogenic HCT116 lines, differing only inMenin, Mad1, or Brit1 readily activated the expression
of hTERT mRNA. We also observed elevated expression their p53 status (Figure 4C, bottom). Thus, using two
different assays, we have been unable to confirm thatof hTERT protein levels when Menin and Mad1 siRNAs
were tested (Figure 4A, bottom). The effects of repressor p53 is repressor of hTERT under physiological condi-
tions. This is consistent with the observation that telo-depletion on hTERT were specific because we did not
observe an effect when siRNAs against LacZ, GFP, merase expression in tumors does not correlate with
p53 status (Sood et al., 2002)Cyclin F, or Claspin were used.
The depletion of SIP1 had no effect on hTERT tran- Among the repressor candidates we identified, we
focused on Menin and Mad1 because of the involvementscription or protein levels, suggesting SIP1 does not
regulate hTERT in U2OS cells under these culture condi- of their pathways in human cancers. Since both Mad1
and Menin are transcriptional repressors, their repres-tions. Recent studies have placed SIP1 as a downstream
transcriptional target of TGF- (Comijn et al., 2001), a cell sive activities on hTERT expression might be manifested
through a direct interaction with the hTERT promoter.inhibitory signal reported to repress hTERT expression
(Yang et al., 2001). We therefore tested whether SIP1 Therefore, we explored binding of these factors to the
hTERT promoter using chromatin immunoprecipitationmight be required for the downregulation of hTERT by
TGF-. Consistent with this hypothesis, the reduction of (CHIP) analysis.
Mad1 is a transcriptional repressor that represseshTERT expression induced by TGF- treatment of MCF-7
cells was partially dependent upon SIP1 (Figure 4B). c-Myc-mediated transactivation by competing for the
ubiquitous binding partner Max from binding to c-Myc.Several studies have suggested that p53 is a negative
regulator of hTERT (Kanaya et al., 2000; Xu et al., 2000). The decreased expression of Mad1 in normal cells could
reduce its antagonistic activity toward c-Myc and, inHowever, these studies relied upon overproduction of
p53. In order to show that p53 is a bona fide repressor of turn, activate genes involved in tumorigenesis, including
hTERT. We detected specific binding of Mad1 to thehTERT, removal of p53 must be able to increase hTERT
expression. To confirm that p53 is a negative regulator hTERT promoter (Figure 5A). Depletion of Mad1 by
siRNA increased the association of c-Myc with theof hTERT, we depleted p53 using siRNA. When p53
expression was inhibited in U2OS cells, no effect on hTERT promoter, presumably through an increase of
c-Myc/Max binding to the promoter. This data is consis-hTERT expression was detected (Figure 4C, top). To
determine whether the inability to detect an effect on tent with published reports (Wang et al., 1998; Takakura
et al., 1999) that Myc is a transcriptional activator of thehTERT was due to an inability to completely eliminate
p53 using siRNA, we next examined HCT116 cells in hTERT promoter.
Menin is the protein product encoded by the potentwhich p53 was deleted using gene targeting (Bunz et
Genetic Repressors of Telomerase Expression
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pressed a small hairpin RNA directed against Menin
(shMenin) (Brummelkamp et al., 2002). The endogenous
Menin expression was significantly reduced in three in-
dependent shMenin clones and led to the reactivation
of hTERT expression as shown in Figure 6A. The reacti-
vation of hTERT expression in BJ-shMenin cells led to an
increase of telomerase activity as determined by TRAP
assays (Figure 6B, left) and in telomerase length as de-
termined by using telomere restriction fragment (TRF)
assays (Figure 6B, right). These three Menin-deficient
clones have exceeded their normal lifespan by at least
45 doublings with no sign of replicative senescence (less
than 5% of cells showed SA--Gal staining versus more
than 90% cells stained positive in the control clones)
(Figure 6C). To date, these cells appear to be immortal-
ized and have continued to proliferate. We have taken
one line through over 200 cell doublings (data not
shown).
Finally, we tested whether Menin-deficient cells were
more susceptible to cellular transformation when ex-
posed to additional oncogenic stimuli. As shown in Fig-
ure 6D, shMenin cells, when transfected with SV40 Large
and Small T antigen and oncogenic ras, escaped contact
inhibition and formed foci in the focus forming assay,
indicating cell transformation had occurred, whereas
control cells lacking shMenin did not form foci (FigureFigure 5. Direct Association of Mad1, c-Myc, Max, and Menin with
6D). These results are similar to the combinatorial effectsthe Promoter of hTERT
of ectopic hTERT, Large T, Small T, and ras shown in(A) Direct association of Mad1, c-Myc, and Max to the promoter of
previous studies using additional transformation assayshTERT. Chromatin was prepared from cells treated or untreated with
siRNA to Mad1 and was immunoprecipitated using the indicated (Hahn et al., 1999).
antibodies. Immunoprecipitated samples were subjected to PCR
analysis using the indicated primers to the hTERT promoter.
Discussion(B) Association of Menin with the hTERT promoter. Chromatin was
prepared from cells treated or untreated with siRNA to Menin as
Understanding hTERT regulation is important for severalindicated. This chromatin was immunoprecipitated using the indi-
cated antibodies. Immunoprecipitated samples were subjected to reasons. First, if hTERT expression is a critical aspect
PCR analysis using the primers indicated on the schematic diagram of tumorigenesis, its regulators should be tumor sup-
of the hTERT promoter. pressor or oncogenes. Secondly, if stem cells express
telomerase and differentiated cells do not, regulatory
pathways that control telomerase expression may betumor suppressor gene MEN1. Mutations in MEN1 result
in multiple endocrine neoplasia type 1 syndrome (Marx critical for maintenance of the stem cell state. Finally,
recent studies have indicated a correlation betweenet al., 1998). It is possible that loss of its repressive
effects on hTERT may directly contribute to the tumor short telomere length and increased mortality (Cawthon
et al., 2003). If these longevity correlations prove correct,development observed in MEN1 patients. Menin has
been shown to antagonize the transcriptional activity of it suggests the possibility that resetting telomere length
through pharmacological manipulation of telomeraseeither JunD on AP1 sites (Agarwal et al., 1999) or NF-
B (Heppner et al., 2001) on its cognate motif. As shown expression could affect mortality. Thus, knowledge of
the regulatory pathways controlling telomerase expres-in Figure 5B, Menin crosslinks to the hTERT promoter,
particularly to the region containing the putative AP1 sion has broad biological implications.
In this study, we have uncovered six genes whoseand NF-B binding sites (amplicon 2). The binding is
much weaker to amplicon 1, which was immediately expression affects hTERT expression and found that
multiple tumor suppressor/oncogene pathways nega-adjacent to amplicon 2. Consistent with this, amplicon
1 contains only a weak AP1 binding sequence. Menin tively regulate human TERT. Genes in three known tumor
suppressor/oncogene pathways, the TGF--Activinbinding was not detected to the -actin promoter, dem-
onstrating the specificity of our CHIP assays. pathway, the MAD-MYC pathway, and the MEN1 path-
way, all work to limit hTERT expression. SIP1 appearsEctopic expression of hTERT has been shown to result
in immortalization of human diploid fibroblasts and to to mediate at least part of the TGF--mediated repres-
sion of hTERT. Mad1 regulates the ability of c-Myc tocontribute to cellular transformation in combination with
expression of SV40 Large and Small T antigen and onco- activate hTERT. Menin is known to act as a negative
regulator of gene expression through its ability to bind togenic ras. Since MEN1 negatively regulates hTERT, loss
of MEN1 may result in similar phenotypes that contribute and inhibit the transactivation ability of several positively
acting transcription factors. Consistent with this viewto its role in tumorigenesis. To test this, we depleted
Menin expression in BJ cells, a primary human diploid of Menin, we observe that Menin physically associates
with the promoter region of hTERT that we used in thefibroblast line, by integrating a vector that stably ex-
Cell
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Figure 6. The Effects of Menin Depletion on the Extension of Lifespan and Susceptibility to Cell Transformation in Human Primary Fibroblasts
(A) Depletion of Menin reactivated hTERT expression in three shMenin BJ clones.
(B) ShMenin BJ clones showed increased telomerase activity compared to parental cells and vector control clone (left). IC standards for the
internal reaction control provided by the TRAPeze kit. The telomere lengths in shMenin cells were extended compared to the BJ-vector clone
with two different population doublings as determined by Southern blotting, using telomeric repeats as probes.
(C) The lifespan measured by population doublings of all three shMenin clones (shMenin1–3) were significantly extended (bottom, closed
symbols) compared to vector controls (open symbols). Senescence as measured by SA--Gal staining was examined for shMenin clones
(top, right) and vector control clones (top, left).
(D) Large T (LT) and Small T (ST) antigens and oncogenic ras expression vectors were introduced into shMenin clones (top, right) or vector
control cells (top, left) and assayed for foci formation. The foci numbers are shown as three individual experiments when 500 shMenin 
LT  ST  ras cells or vector  LT  ST  ras cells were seeded with 105 BJ cells in 10 cm dishes.
(E) A model summarizing the action of repressors on the hTERT promoter. Repressive proteins are shown in red and activating proteins in
green. Rak, BRIT1, and hSir2 are arbitrarily shown to act through independent pathways, but it is possible that they act through the same
pathway or one of the other three known pathways shown.
original screen to drive GFP. The proteins through which has been implicated in promoting longevity in both S.
cerevisiae (Guarente and Kenyon, 2000) and C. elegansMenin acts at the hTERT promoter are unknown, al-
though JunD and/or NF-B are potential candidates me- (Tissenbaum and Guarente, 2001) and telomerase pro-
motes cell longevity in cultured cells, it is possible thatdiating this activity.
Two other less studied genes, RAK and BRIT1, are this aspect of hSIR2 activity may represent a conserved
feature of Sir2 function as a global promoter of longevityalso implicated in hTERT regulation and are therefore
potential tumor suppressors. As RAK encodes a protein in eukaryotes.
Telomere length has been suggested to be linked tokinase, it may represent a fourth signaling pathway that
impinges on hTERT expression. Understanding what aging in animals and cell immortality in cell culture. The
expression of hTERT has been shown to stimulate telo-pathway regulates RAK will be important for under-
standing the higher-level organization of hTERT regula- merase activity in several cell types (Counter et al., 1998;
Morales et al., 1999; Jiang et al., 1999; Rufer, et al. 2001;tion. In addition, we found that hSIR2 appears to play
a positive role on hTERT transcription, although given its Stampfer et al., 2001; Simonsen et al., 2002) and to
bypass the senescence program of human fibroblastsfunction, this is likely to be indirect, and how it controls
hTERT will require further analysis. However, as Sir2 in vitro (Morales et al., 1999; Jiang et al., 1999; Zhu et
Genetic Repressors of Telomerase Expression
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al., 1999). Our results confirm this critical observation have long-term palliative consequences in these circum-
as loss of MEN1 function leads to a bypass of the senes- stances without the risk of enhancing tumorigenesis.
cence pathway, consistent with its role as a negative Thus, this collection of genes and the others to be found
regulator of hTERT expression. Even though expression through completion of this screen may have important
of a single gene, hTERT, can induce immortalization, medical applications in the future.
spontaneous immortalization is rare, less than one in
Experimental Procedures107 cells (Wright et al., 1989; Counter et al., 1992; Stewart
and Weinberg, 2002). Given these multiple mechanisms
Cell Lines, Plasmids, and Antibodiesof inducing hTERT expression, why it is so rare is not
All cell lines except BJ-hTERT were purchased from ATCC (Rock-understood. We favor the explanation that although
ville, MD). Cells were grown in DMEM supplemented with 10% fetal
there are likely to be several genes whose loss can calf serum except U2OS cells were grown in McCoy’s Medium in-
induce hTERT, since these cells have normal genomic stead. BJ-hTERT was kindly provided by Dr. William Hahn. The
hTERT-2k GFP reporter was constructed by subcloning 2 kb ofstability, the frequency with which both alleles of a given
hTERT promoter (30 to 1970, ATG as 1) into a promoterlessgene would be lost is extremely rare.
EGFP vector (Clontech). The enhanced retroviral mutagen (ERM)The fact that three known tumor suppressor/onco-
vector (Liu et al., 2000) was a gift from Dr. Z. Songyang. The expres-gene pathways were identified in this screen argues
sion vectors were generous gifts from Dr. A.L. Burns (Menin), Dr.
strongly for the notion that telomerase activity is specifi- R.A. Weinberg (hSir and dnSir retroviral vectors), Dr. D.C. Dean
cally reactivated in tumors and that these tumors are (SIP1), and Dr. T.K. Kim (Mad1). Rak was cloned by RT-PCR and
derived from cells that initially did not express telo- subcloned into the pcDNA3 vector. The hTERT antibody was pur-
chased from Calbiochem. The antibodies against Menin (sc-8200),merase or were destined to repress it. Short of finding
Mad1 (sc-222), c-Myc (sc-764), and Max (sc-197) were all purchasedalterations in the hTERT gene itself in tumors, finding
from Santa Cruz Biotechnology.that multiple tumor suppressor/oncogene pathways
control hTERT expression is among the strongest evi-
siRNAdence that hTERT expression is actually contributing to
All RNA oligos were purchased from Dharmacon Research (Lata-
tumor formation. It is easy to argue that a given down- yette, CO). Oligos were transfected twice using Oligofectamine (In-
stream target of a single cancer-causing mutation may vitrogen), and the RNAs or nuclear extracts were collected 2 days
not be causal for tumorigenesis, i.e., Myc overproduc- after the second transfection. The sequences of siRNAs employed
are: Menin: 5-CAGCCUCAGCCGCUCCUACdTdT-3, 5-GUAGGAGtion controls many genes, some of which have nothing
CGGCUGAGGCUGdTdT-3; Rak: 5-GCGAUUGGGAUCUGGUCAGto do with tumorigenesis. However, the finding that mul-
dTdT3, 5-CUGACCAGAUCCCAAUCGCdTdT-3; SIP1: 5-CUGCCtiple pathways known to be involved in tumorigenesis
AUCUGAUCCGCUCUdTdT-3, 5-AGAGCGGAUCAGAUGGCAGd
regulate the same gene greatly enhances the probability TdT-3; hSir2: 5-CUGGAGCUGGGGUGUCUGUdTdT-3, 5-ACAGAC
that the expression of that gene participates in the gen- ACCCCAGCUCCAGdTdT-3; BRCT1: 5-AGGAAGUUGGAAGGAUC
eration of cancer. CAdTdT-3, 5-UGGAUCCUUCCAACUUCCUdTdT-3; Mad1: 5-GUC
GACACACUACGUUGAGdTdT-3, 5-CUCAACGUAGUGUGUCGACA strength of the screening method employed here is
dTdT-3; and p53: 5-GACUCCAGUGGUAAUCUACdTdT-3, 5-GUAthat it has the ability to activate transcription of nonex-
GAUUACCACUGGAGUCdTdTT-3. To construct the vector encod-pressed genes in a given cell, thereby increasing the
ing shRNA against Menin, the Menin siRNA sequences shown abovenumber of genes that can be interrogated. It should be
(using DNA instead of RNA oligos) were subcloned into the pSUPER
noted that this type of screen could be generally applied vector as described previously (Brummelkamp et al., 2002).
to search for activators or repressors of any transcrip-
tional target. In addition, we examined only six genes RT-PCR and Western Blot Analysis
from insertions from an ERM vector using only a single Analysis of hTERT and GAPDH mRNA expression was performed by
RT-PCR amplification as described (Nakamura et al., 1997). hTERTreading frame to trap genes. As we failed to isolate
mRNA was amplified using the primer pair 5-CGGAAGAGTGTCTGthe same gene twice, we are far from saturation and,
GAGCAA-3 (LT5) and 5-GGATGAAGCGGAGTCTGGA-3 (LT6) fortherefore, there are likely to be a great number of genes
31 cycles (94C for 45 s, 60C for 45 s, 72C for 90 s). GAPDH mRNAin this regulatory network that are directly or indirectly
was amplified using primers 5-CTCAGACACCATGGGGAAGG
involved in the regulation of hTERT transcriptional activ- TGA-3 (K136) and 5-ATGATCTTGAGGCTGTTGTCATA-3 (K137)
ity, thereby implicating a large number of genes in this for 16 cycles (94C for 45 s, 55C for 45 s, 72C for 90 s). Reaction
aspect of tumorigenesis. These genes and additional products were then resolved on 2% agarose gel. Nuclear proteins
were extracted as described previously (Minamino et al., 2001).candidates from the saturation of this screen will serve
as a starting point for dissection of the pathways control-
Chromatin Immunoprecipitation (CHIP) Assaysling hTERT expression and are likely to uncover addi-
The CHIP assays were performed as described by Xu et al. (2001).tional novel tumor suppressors. Furthermore, these
Briefly, logarithmically growing cells were fixed with formaldehydegenes and the pathways they reside in may be important
(final concentration 1% vol/vol) in serum-free DMEM medium at 4C
for the ability of stem cells to differentiate. In addition, for 1 hr. Glycine was added to a final concentration of 0.125 M to stop
they may serve as pharmalogical targets for the induc- the crosslinking reaction. Fixed cells were pelleted by centrifugation
tion of telomerase activity in vivo. It has been suggested and washed each in buffer A (10 mM Tris-HCl [pH 8.0], 10 mM EDTA,
that restoring the proliferative potential of cells through 0.5 mM EGTA, and 0.25% Triton X-100) and buffer B (10 mM Tris-
HCl [pH 8.], 200 mM NaCl, 1mM EDTA, and 0.5 mM EGTA). Thetelomerase activation may help diseases such as cirrho-
cells were then resuspended in RIPA (10 mM Tris-HCl [pH 8.0], 140sis of the liver brought on by viral infection or alcohol
mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, and 0.1%abuse. Likewise, support has recently emerged for the
deoxycholate) and were sonicated to make soluble chromatin. Sam-
idea that several of the phenotypes observed in ataxia ples of total chromatin were taken at this point to use as a loading
telangiectasia patients derive from shortened telomeres control (input) in the PCRs. The cell lysates were precleared by
and premature depletion of stem cells (Wong et al., incubation with protein A/G-agarose beads and then incubated with
various antibodies overnight at 4C. DNA-protein complexes were2003). Transient induction of telomerase function may
Cell
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collected with protein A/G-agarose beads followed by intensive tumor formation by mouse cells lacking telomerase RNA. Cell 91,
25–34.washing. Bound DNA-protein complexes were eluted with two incu-
bations in elution buffer (10 mM Tris [pH 8.0], 1 mM DTT, and 0.5% Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A system
SDS) at room temperature for 10 min. A second immunoprecipitation for stable expression of short interfering RNAs in mammalian cells.
was carried out to increase specificity with the use of the same Science 296, 550–553.
protocol. Crosslinks were reversed by the sequential addition of
Bryan, T.M., Englezou, A., Dalla-Pozza, L., Dunham, M.A., and Red-
RNase A and proteinase K and incubation at 65C for 5 hr. Samples
del, R.R. (1997). Evidence for an alternative mechanism for main-
were then extracted twice with phenol/chloroform and precipitated
taining telomere length in human tumors and tumor derived cell
with ethanol overnight. DNA fragments were recovered by centrifu-
lines. Nat. Med. 3, 1271–1274.
gation, resuspended in ddH2O, and used for PCR amplifications.
Bunz, F., Hwang, P.M., Torrance, C., Waldman, T., Zhang, Y., Dil-
lehay, L., Williams, J., Lengauer, C., Kinzler, K.W., and Vogelstein,
shMenin Stable BJ Cell Clones and SA--Gal Staining
B. (1999). Disruption of p53 in human cancer cells alters the re-
The shMenin construct or the pSUPER empty vector were cotrans-
sponses to therapeutic agents. J. Clin. Invest. 104, 263–269.
fected with 1/10 the amount of puromycin-resistant vector into an
Cawthon, R.M., Smith, K.R., O’Brien, E., Sivatchenko, A., and Kerber,early passage of BJ cells. After puromycin selection (750 ng/ml),
R.A. (2003). Association between telomere length in blood and mor-stable clones were tested for Menin expression. Three clones show-
tality in people aged 60 years or older. Lancet 361, 393–395.ing the most Menin depletion were expanded for senescence experi-
ments and the focus forming assays. SA--Gal staining was done Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven,
as described previously (Dimri et al., 1995). L., Bruyneel, E., Mareel, M., Huylebroeck, D., and van Roy, F. (2001).
The two-handed E box binding zinc finger protein SIP1 downregu-
lates E-cadherin and induces invasion. Mol. Cell 7, 1267–1278.Telomerase Activity and Telomere Length
Telomerase activity was determined using the TRAPeze telomerase Cong, Y.S., Wright, W.E., and Shay, J.W. (2002). Human telomerase
detection kit (Intergen, Purchase, NY). Extension of oligonucleotide and its regulation. Microbiol. Mol. Biol. Rev. 66, 407–425.
substrates by hTERT enzymatic activity was followed by PCR in Counter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider,
the presence of 32P-labeled TS primer and 36-base internal assay C.W., Harley, C.B., and Bacchetti, S. (1992). Telomere shortening
standard. Mean telomere length was determined by the telomere associated with chromosome instability is arrested in immortal cells
restriction fragment (TRF) assay as described before (Ouellette et which express telomerase activity. EMBO J. 11, 1921–1929.
al., 2000).
Counter, C.M., Hahn, W.C., Wei, W., Caddle, S.D., Beijersbergen,
R.L., Lansdorp, P.M., Sedivy, J.M., and Weinberg, R.A. (1998). Disso-
Focus Forming Assay ciation among in vitro telomerase activity, telomere maintenance,
shMenin or vector control cells were cotransfected with vectors and cellular immortalization. Proc. Natl. Acad. Sci. USA 95, 14723–
expressing Large T and Small T (Lusky and Botchan, 1981), H-ras 14728.
(Reardon and Hung, 1993), and 1/10 amount of neo-resistant vector.
Craven, R.J., Cance, W.G., and Liu, E.T. (1995). The nuclear tyrosineAfter G418 drug selection, 500 cells (stable pool) were mixed with
kinase Rak associates with the retinoblastoma protein pRb. Cancer105 BJ cells in 10 cm dishes, After 3 weeks, cells were stained with
Res. 55, 3969–3972.2% methylene blue to detect foci.
de Lange, T. (1994). Activation of telomerase in a human tumor.
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